Who Owns Avanos Company?

Avanos Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Avanos Medical?

Understanding the ownership structure of a company is crucial for investors and anyone interested in its future. Avanos Medical (AVNS), a key player in medical technology, has a fascinating ownership journey. From its spin-off from Kimberly-Clark to its current status, the evolution of Avanos SWOT Analysis reveals valuable insights into its strategic direction.

This exploration of Avanos ownership will uncover the key stakeholders shaping its destiny. We'll examine the significant shifts in Avanos company ownership, from its initial public offering to the current ownership details. Knowing who owns Avanos provides a deeper understanding of the company's potential and its commitment to its mission, especially considering its headquarters location and the leadership team's influence.

The story of Avanos Medical, and the question of who owns Avanos, begins not with a traditional startup but with a strategic spin-off. The company, now known as Avanos Medical, started its independent journey on October 31, 2014, after separating from Kimberly-Clark Corporation. Initially, it operated under the name Halyard Health, Inc.

As a spin-off, the initial leadership of Avanos company comprised executives from Kimberly-Clark's healthcare division. Robert E. Abernathy was the first CEO of the newly independent Halyard Health. The company's early financial foundation came from the assets and liabilities transferred from Kimberly-Clark's healthcare business during the spin-off.

Shares of Halyard Health, Inc. were distributed to existing Kimberly-Clark shareholders, and the company became publicly traded on the New York Stock Exchange (NYSE) under the ticker HYH. The initial ownership structure was thus tied to Kimberly-Clark's existing shareholder base.

Spin-off Origins

Avanos Medical emerged as a spin-off from Kimberly-Clark, marking a departure from typical startup origins. This strategic move shaped its initial ownership and operational structure.

Initial Leadership

The early leadership team was primarily composed of executives from Kimberly-Clark's healthcare division. Robert E. Abernathy served as the first CEO, guiding the company through its initial independent phase.

Public Trading

Avanos stock began trading on the NYSE under the ticker HYH, providing public access to its shares. This marked a significant step in its evolution as an independent entity.

Shareholder Base

The initial distribution of Avanos ownership was linked to Kimberly-Clark's existing shareholders. This provided a foundational investor base as the company launched its independent operations.

Focus

The company's vision, rooted in Kimberly-Clark's healthcare division, centered on medical technology and supplies. This focus drove its early product development and market strategy.

Ownership Details

Specific equity splits or shareholding percentages for individual 'founders' are not readily available. The initial ownership distribution was tied to Kimberly-Clark's existing shareholder base.

Key Aspects of Early Ownership

Understanding the early ownership structure of Avanos Medical is crucial for investors and stakeholders. This structure, born from a spin-off, differs significantly from traditional startups. For more details, you can read this article about Avanos Medical.

• The initial ownership was distributed to existing Kimberly-Clark shareholders.
• The company's focus was on medical technology and supplies.
• There are no readily available details on specific equity splits for individual founders.
• Avanos Medical began trading on the NYSE under the ticker HYH.

Avanos SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Avanos Medical has transformed significantly since its spin-off. Initially known as Halyard Health, Inc., the company rebranded to Avanos Medical, Inc. in June 2018. This shift marked a new chapter for the medical technology firm, influencing its strategic direction and investor relations. Understanding the evolution of Avanos's mission is key to grasping its current ownership dynamics.

As of May 2025, the majority of Avanos ownership is held by institutional investors, indicating strong confidence from the financial market. This ownership structure plays a critical role in shaping corporate governance and influencing strategic decisions. The company's history includes strategic moves such as the acquisition of Diros Technology Inc. for approximately $53.0 million, which has further shaped its financial landscape.

Institutional investors hold a significant portion of Avanos stock. As of May 2025, institutional investors own approximately 91.14% of the company's stock, with insiders holding 2.06%. Public companies and individual investors account for 15.23%. Key institutional shareholders as of March 30, 2025, include BlackRock, Inc. (14.91% holding, 6,896,968 shares), Vanguard Group Inc. (11.57% holding, 5,348,297 shares), and T. Rowe Price Investment Management, Inc. (8.13% holding, 3,757,576 shares). Notable shifts in shareholding include T. Rowe Price Investment Management, Inc. increasing its holding by 24.78% and Armistice Capital, LLC increasing its holding by 100% as of March 30, 2025.

Avanos Ownership Insights

Avanos Medical's ownership is primarily held by institutional investors, reflecting market confidence.

• Institutional investors hold approximately 91.14% of the stock.
• BlackRock, Inc. and Vanguard Group Inc. are major shareholders.
• Significant changes in shareholding occurred as of March 30, 2025.
• The company's headquarters is located in Alpharetta, Georgia.

Avanos PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current Board of Directors of Avanos Medical plays a vital role in the company's governance. At the annual meeting held on April 24, 2025, stockholders elected five directors to serve one-year terms. These directors include Gary D. Blackford, Dr. Lisa Egbuonu-Davis, Indrani L. Franchini, Patrick J. O'Leary, and Dr. Julie Shimer. Each director received over 36 million votes, reflecting strong shareholder support.

This demonstrates a high level of confidence in the current leadership. The board's decisions are crucial for the company's strategic direction and financial performance. Understanding the composition of the board is essential for anyone looking into Avanos's target market and overall business strategy.

Avanos Medical operates under a one-share-one-vote structure. This means that each holder of common stock is entitled to one vote per share. However, certain significant corporate actions, such as dissolving the corporation or selling most of its assets, might need approval from two-thirds of the voting power of all capital stock, unless the Board of Directors waives this requirement. Amendments to the company's by-laws also require an 80% affirmative vote or action by the Board of Directors.

Avanos Medical's Governance Structure

Avanos Medical's governance structure is designed to ensure shareholder interests are represented and protected. The company uses a one-share-one-vote system.

• The board of directors is elected by shareholders.
• Significant corporate actions require specific voting thresholds.
• There are no known dual-class shares or founder shares.

Avanos Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, there have been significant shifts in the ownership profile and strategic direction of Avanos Medical. The company's commitment to returning value to investors is evident through its stock repurchase program. Announced on November 1, 2024, the program authorized the buyback of up to $25 million of its common stock over the next year. By January 2025, Avanos had already repurchased $85 million worth of shares, with plans to utilize the remaining program funds to support organic growth and potential mergers and acquisitions.

Leadership changes also marked this period. Michael C. Greiner, who served as Interim CEO from October 28, 2024, left on April 18, 2025, following the appointment of Dave Pacitti as the new CEO on April 14, 2025. Additionally, Jason M. Pickett was appointed Interim Chief Financial Officer on the same date. These changes are expected to bring fresh perspectives and strategic direction to the company. The company's focus on strategic mergers and acquisitions (M&A) opportunities aligns with its return criteria, as seen by the closure of two smaller transactions in early 2025 to support its specialty nutrition system strategy.

The medical technology sector is seeing increased institutional ownership, and Avanos Medical reflects this trend, with institutional investors holding over 91% of its shares as of May 2025. The company's focus on organic product development, particularly in areas like COOLIEF Cooled Radiofrequency systems, and targeted acquisitions, reflects its strategy to compete in the evolving medical device industry. For 2025, Avanos Medical projects net sales between $665 million and $685 million and adjusted diluted earnings per share between $1.05 and $1.25. To understand the competitive environment, you can explore the Competitors Landscape of Avanos.

Avanos Ownership Structure

Avanos Medical is a publicly traded company, with a significant portion of its shares held by institutional investors. The company's ownership structure is primarily driven by institutional holdings.

Recent Financial Performance

Avanos Medical projects net sales between $665 million and $685 million for 2025. The company also anticipates adjusted diluted earnings per share between $1.05 and $1.25 for the same period.

Leadership Changes

Dave Pacitti was appointed as the new CEO on April 14, 2025, and Jason M. Pickett was appointed Interim Chief Financial Officer on the same date. These changes are expected to bring fresh perspectives.

Strategic Initiatives

Avanos Medical is actively pursuing strategic mergers and acquisitions (M&A) opportunities. The company completed the sale of its Respiratory Health business in 2024 and acquired Diros Technology Inc.

Avanos Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs